कोशिश गोल्ड - मुक्त

10-point guide to Bihar results

Business Standard

|

November 15, 2025

The outcome marks the end of Lalu as a political force. While Nitish’s phase is a matter of time, the BJP has a hawk’s eye. If only they could find some serious local leadership

- SHEKHAR GUPTA

10-point guide to Bihar results

Here we go with our 10 quick takeaways from this Bihar election result.

The first is that however incredible this landslide might look, the ossified vote banks remain. As fights become more direct, either between two parties or alliances, the gap between a rout and a landslide can be just a few percentage points. The JDU got 15.39 per cent vote in 2020 and it has now gone up by about 4 percentage points to 19.26 (provisional figures at the time of writing). The BJP has risen, but only by a percentage point to 20.11 (provisional figures). Both have contested in a few seats fewer but let’s read that as marginal because these have gone to their allies. The most important ally, the Paswan dynasty’s Lok Janshakti Party (LJP), for example, contested just 29 seats this time, compared to 135 in 2020. Its vote percentage has remained frozen at just over§ percent. It’s evident that in the other constituencies, its tiny vote parcels must've gone to the BJP or JDU.

Now, flip the coin. The Rashtriya Janata Dal’s vote share has remained almost constant at around 23 per cent, as has the Congress’s around 9 per cent. It is clear, therefore, that the two alliance partners have not lost any vote share. It is just that the National Democratic Alliance (NDA) has built a better alliance with the LJP and Jitan Ram Manjhi’s Hindustani Awam Morcha (HAM) to build that additional 5-8 per cent kicker over frozen BJP/JDU votes. That kicker is the difference between a rout and a landslide. This is the central message of this election. The rival cannot take away your committed voters. You have to stitch alliances to bring in the “others”.

Business Standard से और कहानियाँ

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size